U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07174336) titled 'A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)' on Sept. 12.
Brief Summary: The purpose of the study is to assess the efficacy and safety of the addition of LY4064809 to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Breast Neoplasms
Neoplasm Metastasis
Inte...